**Study Overview:** This is an early-phase trial to test a new drug, **PLN-101095**, with pembrolizumab for people with serious or spread-out (metastatic) tumors. **Pembrolizumab** is a medicine that helps the immune system fight cancer. The study checks **safety**, **tolerability**, and how well the treatment works against cancer. Participants must have advanced tumors that worsened despite previous pembrolizumab treatment.
**Study Structure:** The study has two parts. **Part 1** increases the drug dose slowly to find safe levels. **Part 2** uses the safe dose to test effectiveness in more people.
**Eligibility:** Participants must have an advanced tumor, have tried pembrolizumab before, and have a life expectancy of at least 3 months. They need at least one measurable tumor and good overall health. Women must not be pregnant or breastfeeding.
**Key Points:**
- **Duration & Visits:** Participants will need to attend several study visits over time.
- **Risks:** Potential risks include side effects from the study drug, especially if you have other health conditions.
- **Compensation:** Participants might receive compensation for their time and travel.
**Consideration:** Ensure you meet the health requirements and understand the potential risks before joining this study.
How understandable was the trial content above?
Hard to understand
Easy to understand